Repurposing hyperpolarization‐activated cyclic nucleotide‐gated channels as a novel therapy for breast cancer

• Published in: Clinical and translational medicine Vol. 11; no. 11; pp. e578 - n/a
• Main Authors: Mok, Ka‐Chun, Tsoi, Ho, Man, Ellen PS, Leung, Man‐Hong, Chau, Ka Man, Wong, Lai‐San, Chan, Wing‐Lok, Chan, Sum‐Yin, Luk, Mai‐Yee, Chan, Jessie Y.W., Leung, Jackie K.M., Chan, Yolanda H.Y., Batalha, Sellma, Lau, Virginia, Siu, David C.W., Lee, Terence K.W., Gong, Chun, Khoo, Ui‐Soon
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.11.2021; John Wiley and Sons Inc; Wiley
• Subjects: Breast cancer; Cell Line - drug effects; Cell Line - physiology; Chemotherapy; Clinical medicine; ER‐stress; FDA approval; Female; HCN; Heart rate; Humans; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels - metabolism; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels - therapeutic use; Ivabradine; Ivabradine - metabolism; Ivabradine - therapeutic use; Lasers; Ontology; Protein expression; Proteins; Research ethics; Review boards; Software; targeted therapy; Triple Negative Breast Neoplasms - drug therapy; triple‐negative breast cancer; Variance analysis; Hong Kong China; United States > US; China; targeted therapy; HCN; triple-negative breast cancer; ER-stress; Ivabradine

Hyperpolarization‐activated cyclic nucleotide‐gated (HCN) channels are members of the voltage‐gated cation channel family known to be expressed in the heart and central nervous system. Ivabradine, a small molecule HCN channel‐blocker, is FDA‐approved for clinical use as a heart rate‐reducing agent....